retatrutide phase 2 trial weight loss is generating a lot of buzz in the medical world—and for good reason. As research continues, many experts believe it could represent the next generation of metabolic health treatments Retatrutide, a TRIPLE agonist (GLP1,

It is majorly found circulating in the blood as GLP-1(7-36) amide that is produced primarily from three tissues of the human body: enteroendocrine L cells in the distal small bowel, cells in the pancreas, and the central nervous system ( Surprisingly, it took approximately 20 years from the discovery of GLP-1 to the authorized approval of worldwide utilized GLP-1 RAs

Where specific remedies and management strategies are referenced, recommendations are based on standard medical practice guidelines from Mayo Clinic, Cleveland Clinic, Johns Hopkins Medicine, and peer-reviewed research

Cardiovascular outcomes A total of 52 meta-analyses (covering 141 outcomes) evaluated GLP-1 RAs for cardiovascular outcomes (Fig

World J Diabetes 10(1):115